Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Completed · Phase 1 · NCT03889912
Conditions: Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
At a glance
- Research payments reported, 2025
- $768,074
- U.S. investigators named
- 10
- Sites paid
- 10
- Planned or actual enrollment
- 97
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Cemiplimab (drug)
- Dates
- Started 2019-04-11; completion 2025-12-10
- Results posted
- Not yet
This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC). The aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as REGN2810). The first part of the study tested several different doses of cemiplimab given weekly for 12 weeks. The study is also looking at several other research questions, including: * What side effects may happen from taking the study drug * To see effect of cemiplimab on the tumor * How much study drug is in the blood at different times
From ClinicalTrials.gov, last updated 2026-01-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $768,074 in research payments for this study in 2025 (101 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nathalie Zeitouni, MD Dermatology · Phoenix, AZ
- Neal D. Bhatia, MD Dermatology · San Diego, CA
- John M. Strasswimmer, M.D. Dermatology · Salida, CO
- Gary S. Rogers, MD Dermatology · Ocala, FL
- Jack L. Arbiser, MD Dermatology · Atlanta, GA
- Georgia Beasley, M.D. Surgical Oncology · Durham, NC
- John A. Carucci, MD Mohs Surgery · Fishkill, NY
- Sherrif F. Ibrahim, MD Mohs Surgery · Victor, NY
- Michael R. Migden, MD Mohs Surgery · Houston, TX
- Jennifer A. Desimone, MD Dermatology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rochester Dermatologic Surgery $164,993
- Ut MD Anderson Cancer Center $162,278
- Metroderm Acc Research $137,752
- Inova Fairfax Hospital, VA $127,895
- Integrity Research Clinical Associates LLC $48,459
- Southwest Skin Specialists LLC $46,691
- Tcr Medical Corporation $25,596
- NYU Grossman School of Medicine $25,415
- Duke University $16,808
- Allcutis Research LLC $12,185
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.